Sign In
Buy ARKG
$33.15
-0.260 (-0.778%)
At Close: Jun 08, 2026
Disruptive Tech ETFs Rally on Encouraging Dialogue Between Russia and Ukraine
05:01pm, Tuesday, 29'th Mar 2022
Disruptive technology-related exchange traded funds rallied on Tuesday as U.S. markets turned risk-on, following positive updates on Russia and Ukraine's negotiations. Among the best-performing non-le
ARKG: Be Patient And Look For A Longer Time Horizon
06:27am, Sunday, 27'th Feb 2022
ARKG has shown better performance over its peers. ARKG has done a overhaul of its portfolio to curb down volatility.
Ark is Sinking - Will Ark Invest Recover?
12:28pm, Thursday, 10'th Feb 2022
Catherine Wood (Trades, Portfolio) (Trades, Portfolio) is a growth stock investor who believes innovation and technology are the keys to great investing returns. Her flagship fund, the Ark Innovation
ARK Faithful Hold Firm—Mostly
12:04pm, Tuesday, 08'th Feb 2022
Year-to-date, 'ARKK' still has inflows, but the other ETFs in ARK's suite have shed assets.
Volatility Is Not a Bad Word With a Long-Term Time Horizon
07:10pm, Friday, 04'th Feb 2022
While disruptive innovation strategies may experience short-term volatility, ARK's research shows that maintaining a long-term investment time horizon is critical for investors searching for potential
7 Megatrend Stock ETFs With Massive Potential
03:18pm, Thursday, 03'rd Feb 2022
In 2022, the U.S. equities market got off to its worst start to a year since the dark days of the financial crisis, with many areas of the market, including stocks and stock exchange-traded funds (ETF
A Bright Outlook for Gene Editing Investing
03:06pm, Wednesday, 02'nd Feb 2022
With biotechnology stocks, particularly those in mid- and small-cap territory, heavily out of favor at the moment, it's not surprising that some investors are ignoring genomics assets. That sentiment
Cerus Corporation: Outperforming And Gaining Momentum
11:37am, Friday, 28'th Jan 2022
Cerus Corporation: Outperforming And Gaining Momentum
Gene Editing Stocks Might Be Building Some Momentum
01:59pm, Wednesday, 12'th Jan 2022
Experienced healthcare and biotechnology investors know that January brings the arrival of the widely followed JPMorgan healthcare conference. This year, it's taking place in virtual fashion, but that
Pfizer/Beam Deal Highlights In Vivo Potential
11:45am, Tuesday, 11'th Jan 2022
It's just one deal, but genomics companies with exposure to in vivo gene editing may be getting a much-needed boost after blue-chip pharmaceuticals company Pfizer (NYSE:PFE) announced a related agreem
Yield Spikes Muddy ARK's Waters
10:37am, Friday, 07'th Jan 2022
Cathie Wood's multibillion-dollar funds are off to a rocky start in 2022.
Worst Performing ETFs Of The Year
11:43am, Thursday, 06'th Jan 2022
The worst performers fell by 25% to 72% over the course of 2021.
Should You Bet on Cathie Wood in 2022?
03:20pm, Wednesday, 05'th Jan 2022
Two of ARK Invest's most popular ETFs were down double digits in 2021. Is it time to buy?
How Did Cathie Wood's ARK Invest Perform in 2021?
01:04pm, Wednesday, 29'th Dec 2021
Let's take a look at how ARK Invest ETFs performed in 2021.
CRISPR Could Come Alive in 2022
11:57am, Wednesday, 29'th Dec 2021
Clustered regularly interspaced short palindromic repeats, colloquially known as CRISPR, is one of the bedrocks of the genomics investment thesis, and it could be poised for big things in 2022. If tha
